| VRTX |
Report |
Total Revenue |
BEAT |
pred ~$3.28B vs. cons $3.23B |
MEDIUM |
| VRTX |
Report |
Non-GAAP EPS |
BEAT |
pred ~$4.90 vs. cons $4.80 |
MEDIUM |
| VRTX |
Report |
JOURNAVX Revenue |
BEAT |
pred ~$85M vs. cons $70M |
LOW |
| VRTX |
Guide |
FY2026 Total Revenue Guidance |
UNCHANGED |
guide ~$12.95-13.1B (reaffirmed, ~$13.02B midpoint) vs. cons $13.0B (FY2026) |
HIGH |
| VRTX |
Guide |
FY2026 Non-CF Revenue Guidance |
UNCHANGED |
guide ~$500M+ vs. cons $500M (FY2026) |
MEDIUM |
| VRTX |
Guide |
FY2026 Combined Non-GAAP Opex Guidance |
UNCHANGED |
guide ~$5.65-5.75B (~$5.70B midpoint) vs. cons $5.70B (FY2026) |
MEDIUM |
| VRTX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| VRTX |
Return |
5-day cumulative residual |
+0.4% (FADE) |
A likely beat-and-reaffirm (rather than beat-and-raise) quarter implies no change to the H2 growth algorithm even after a Q2 beat, effectively an implicit trim to the run-rate needed to hit the top end of FY26 guidance; combined with lingering overhang from Crinetics financing/dilution commentary (term loan costs, no accretion until 2029) and no confirmed close-date catalyst, initial relief-rally gains from solid CF/JOURNAVX/CASGEVY execution and povetacicept PDUFA color should partially fade over the following days as analysts model out reiterated (not raised) guidance and financing costs. |
MEDIUM |